Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Growing
The company is in a growing phase, with the latest annual income totaling USD 70.39M.
Undervalued
The company’s latest PE is -4.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 66.34M shares, decreasing 17.31% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 210.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.24.